Literature DB >> 1416869

Susceptibilities of ampicillin-resistant strains of Salmonella other than S. typhi to 10 antimicrobial agents.

J I Alós1, J L Gómez-Garcés, R Cogollos, E Amor, A Pérez-Rivilla.   

Abstract

Ampicillin-resistant strains of Salmonella other than S. typhi constitute a health problem. We tested the antimicrobial susceptibilities to 10 antibiotics of 57 of these strains isolated in a 30-month period. The rates of resistance were as follows: chloramphenicol, 40.3%; tetracycline, 33.3%; gentamicin, 5.3%; co-trimoxazole, 5.3%; nalidixic acid, 1.8%; and amoxicillin-clavulanic acid, cefotaxime, ceftriaxone, aztreonam, and ciprofloxacin, 0%. In our experience, there are alternative antibiotics with excellent in vitro activities.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416869      PMCID: PMC192052          DOI: 10.1128/AAC.36.8.1794

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Quinolones for the treatment of infections due to Salmonella.

Authors:  C E Cherubin; R H Eng
Journal:  Rev Infect Dis       Date:  1991 Mar-Apr

2.  The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections.

Authors:  J M Aguiar; J Chacon; R Canton; F Baquero
Journal:  J Antimicrob Chemother       Date:  1992-03       Impact factor: 5.790

3.  Identification of CTX-2, a novel cefotaximase from a Salmonella mbandaka isolate.

Authors:  M C Poupart; C Chanal; D Sirot; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

4.  Quinolone resistance in Salmonella spp: veterinary pointers.

Authors:  L J Piddock; C Wray; I McClaren; R Wise
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

5.  Quinolone resistance in salmonella: clinical experience.

Authors:  L J Piddock; K Whale; R Wise
Journal:  Lancet       Date:  1990-06-16       Impact factor: 79.321

6.  Antibiotic resistance among Salmonella from human and other sources in New Zealand.

Authors:  H M Heffernan
Journal:  Epidemiol Infect       Date:  1991-02       Impact factor: 2.451

Review 7.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 8.  Antibiotic resistance of Salmonella in Europe and the United States.

Authors:  C E Cherubin
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

9.  Possible in-vivo transfer of beta-lactamase TEM-3 from Klebsiella pneumoniae to Salmonella kedougou.

Authors:  M Archambaud; G Gerbaud; E Labau; N Marty; P Courvalin
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

10.  Antimicrobial susceptibilities and beta-lactamase production of Hong Kong isolates of gastroenteric salmonellae and Salmonella typhi.

Authors:  J M Ling; G M Zhou; T H Woo; G L French
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

View more
  4 in total

1.  Changes in susceptibility of Salmonella enteritidis, Salmonella typhimurium, and Salmonella virchow to six antimicrobial agents in a Spanish hospital, 1980-1994.

Authors:  J M Ramos; J M Alés; M Cuenca-Estrella; R Fernández-Roblas; F Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

Review 2.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 3.  The epidemiology of bacterial resistance to quinolones.

Authors:  J F Acar; T F O'Brien; F W Goldstein; R N Jones
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 4.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.